<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17921" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Asthma Medication in Children</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chu</surname>
            <given-names>Rebecca</given-names>
          </name>
          <aff>NYU Winthrop Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bajaj</surname>
            <given-names>Puneet</given-names>
          </name>
          <aff>Geisinger Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rebecca Chu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Puneet Bajaj declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17921.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Asthma typically presents with a history of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough and is characterized by chronic airway inflammation. In adults and older children, the diagnosis of asthma can be confirmed by spirometric evaluation, but asthma&#x000a0;is a diagnostic challenge in younger children, typically school-aged. A careful history, exam, trigger factors, response to bronchodilator medications, and family history can help establish asthma diagnosis in this age group.</p>
        <p>This&#x000a0;course highlights a stepwise approach to interprofessional asthma evaluation and treatment and discusses the medications used for rescue and control. Since the approach to a stepwise&#x000a0;escalation or de-escalation of medication options differs depending on where the patient presents, these practice guidelines are highlighted.&#x000a0;Biologics and immunotherapies are also discussed for refractory or chronic presentations, emphasizing adverse drug reactions (ADR) for all classes. Participating clinicians gain a specialized understanding of asthma&#x000a0;medication in children, involving professionals from allied health professions such as nurses, technicians, and, in particular, pediatricians.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Interpret&#x000a0;the signs and symptoms of asthma in the pediatric population.</p></list-item><list-item><p>Identify medication classes that&#x000a0;are used to treat children with asthma.</p></list-item><list-item><p>Interpret&#x000a0;how a stepwise treatment algorithm addresses asthma severity and control.</p></list-item><list-item><p>Collaborate to provide&#x000a0;interprofessional care for&#x000a0;children with asthma to improve their quality of life.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17921&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17921">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17921.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Asthma is the most common chronic respiratory disease of childhood, with approximately 14% of children affected worldwide.&#x000a0;Asthma is characterized by chronic airway inflammation, mucus hypersecretion, and hyper-responsiveness.<xref ref-type="bibr" rid="article-17921.r1">[1]</xref>&#x000a0;A triad of wheezing, shortness of breath, and cough&#x000a0;indicates pediatric asthma.<xref ref-type="bibr" rid="article-17921.r2">[2]</xref> In adults, the diagnosis of asthma can&#x000a0;be confirmed&#x000a0;by spirometric evaluation, but managing asthma is&#x000a0;challenging in pediatric patients. A careful history, exam, trigger factors, response to bronchodilator medications, family history, and FeNO testing can be useful in establishing asthma diagnosis in this age group.<xref ref-type="bibr" rid="article-17921.r3">[3]</xref></p>
        <p>Asthma should be suspected&#x000a0;in children with a history of wheezing&#x000a0;if the following&#x000a0;symptoms&#x000a0;are noted:</p>
        <list list-type="bullet">
          <list-item>
            <p>Wheezing or coughing&#x000a0;exacerbated by&#x000a0;physical&#x000a0;exercise or activity</p>
          </list-item>
          <list-item>
            <p>Laughing or crying in the absence of apparent&#x000a0;respiratory infection</p>
          </list-item>
          <list-item>
            <p>A history of allergic disease (eczema or allergic rhinitis) or asthma in first-degree relatives</p>
          </list-item>
          <list-item>
            <p>Clinical improvement during 2 to 3 months of controller&#x000a0;treatment and worsening after cessation</p>
          </list-item>
          <list-item>
            <p>Symptoms triggered by upper respiratory tract infections, exercise, stress, and environmental exposure to allergens and tobacco smoke.<xref ref-type="bibr" rid="article-17921.r4">[4]</xref><xref ref-type="bibr" rid="article-17921.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>This article primarily reflects pediatric asthma management according to&#x000a0;NAEPPCC (National Asthma Education and Prevention Program Coordinating Committee) and&#x000a0;NHLBI (National Heart, Lung, and Blood Institute).<xref ref-type="bibr" rid="article-17921.r6">[6]</xref>&#x000a0;The Global Initiative for Asthma (GINA) has recently published guidelines for asthma management.<xref ref-type="bibr" rid="article-17921.r7">[7]</xref></p>
        <p>
<bold>Medications, Biologics, and Immunotherapy for Pediatric Asthma</bold>
</p>
        <p><bold>Short-acting beta-2 agonists (SABA):</bold> Albuterol (salbutamol), levalbuterol, and terbutaline are used as quick relief therapy or rescue therapy to&#x000a0;ease symptoms as they reverse bronchoconstriction.<xref ref-type="bibr" rid="article-17921.r8">[8]</xref></p>
        <p><bold>Long-acting beta-2 agonist (LABA):</bold> Formeterol and salmeterol are long-acting beta-2 agonists. Formoterol&#x000a0;stimulates&#x000a0;intracellular adenyl cyclase and increases&#x000a0;cyclic AMP levels, causing the relaxation of bronchial smooth muscles. ICS-formoterol has also been used as a reliever or quick relief&#x000a0;therapy in GINA guidelines.<xref ref-type="bibr" rid="article-17921.r7">[7]</xref><xref ref-type="bibr" rid="article-17921.r9">[9]</xref></p>
        <p><bold>Long-acting muscarinic antagonist (LAMA):</bold> Tiotropium is a long-acting muscarinic antagonist that&#x000a0;inhibits M3 receptors&#x000a0;in the lung's smooth muscle, leading to bronchodilation.<xref ref-type="bibr" rid="article-17921.r10">[10]</xref></p>
        <p><bold>Inhaled corticosteroids (ICS):</bold> Commonly used ICS are budesonide, fluticasone, and mometasone.<xref ref-type="bibr" rid="article-17921.r11">[11]</xref>&#x000a0;Inhaled corticosteroids suppress airway inflammation and&#x000a0;downregulate&#x000a0;proinflammatory&#x000a0;mediators. Corticosteroids are also helpful in preventing airway remodeling. In addition, corticosteroids augment the expression of &#x003b2;-2 receptors in the lung and&#x000a0;increase responsiveness to SABA and LABA therapy.<xref ref-type="bibr" rid="article-17921.r12">[12]</xref></p>
        <p><bold>Systemic corticosteroids:</bold> Commonly used systemic corticosteroids include prednisone, dexamethasone, and methylprednisolone.&#x000a0;Systemic glucocorticoids reduce&#x000a0;airway hyperresponsiveness&#x000a0;and airway inflammation, improve lung function and quality of life, and reduce mortality in acute exacerbation. In addition,&#x000a0;they decrease&#x000a0;capillary permeability,&#x000a0;airway edema, and secretions.<xref ref-type="bibr" rid="article-17921.r13">[13]</xref><xref ref-type="bibr" rid="article-17921.r14">[14]</xref></p>
        <p><bold>Leukotriene receptor antagonist (LTRA):</bold> The leukotriene modifier, montelukast, is the leukotriene&#x000a0;antagonist available in either granules or chewable tablets, depending on the age. It is an alternative option, either alone or in combination with inhaled corticosteroids, depending on the level of asthma severity and control. The leukotrienes LTC4, LTD4,&#x000a0;and LTE4 are&#x000a0;potent mediators of antigen-induced smooth muscle contraction. Montelukast antagonizes these compounds at their receptor, protecting against bronchoconstriction. In addition,&#x000a0;leukotrienes&#x000a0;bind to cysteinyl leukotriene (CysLT) receptors. Montelukast inhibits the CysLT1 receptor and downregulates inflammation.<xref ref-type="bibr" rid="article-17921.r15">[15]</xref>&#x000a0;Zafirlukast is also a recommended option.<xref ref-type="bibr" rid="article-17921.r16">[16]</xref></p>
        <p><bold>5-lipoxygenase inhibitor:</bold>&#x000a0;Zileuton is an inhibitor of 5-lipoxygenase(5-LOX) and inhibits leukotriene formation, reducing airway inflammation.<xref ref-type="bibr" rid="article-17921.r17">[17]</xref></p>
        <p><bold>Mast cell stabilizers:</bold> Mast cell stabilizers used in asthma include sodium cromoglycate (cromolyn sodium) and nedocromil (off-label). Cromolyn sodium inhibits mast cell degranulation after exposure to antigens and inhibits the release of mediators from mast cells.&#x000a0;Cromolyn also&#x000a0;reduces bronchospasm induced by exercise, aspirin, cold air, and environmental pollutants.<xref ref-type="bibr" rid="article-17921.r18">[18]</xref><xref ref-type="bibr" rid="article-17921.r19">[19]</xref></p>
        <p><bold>Methylxanthine:</bold> Theophylline inhibits PDE III and adenosine receptors. Theophylline leads to bronchodilation&#x000a0;mediated by smooth muscle relaxation by inhibiting the phosphodiesterase-III enzyme and has a prophylactic effect.<xref ref-type="bibr" rid="article-17921.r20">[20]</xref></p>
        <p><bold>Anti-IgE antibody:</bold> Omalizumab is a monoclonal&#x000a0;antibody that&#x000a0;inhibits the binding of IgE to the IgE receptor on the surface of mast cells and prevents the mast cell degranulation and release of inflammatory mediators such as IL-4, IL-5, and IL-13.<xref ref-type="bibr" rid="article-17921.r21">[21]</xref></p>
        <p><bold>Anti-interleukin-5 monoclonal antibody:</bold> Mepolizumab is an IL-5 antagonist. IL-5 is the primary cytokine responsible for eosinophils' maturation, recruitment, and activation. Administration of mepolizumab leads to decreased eosinophilia and reduced airway inflammation.<xref ref-type="bibr" rid="article-17921.r22">[22]</xref></p>
        <p><bold>Anti-interleukin-5 receptor alpha monoclonal antibody:</bold> Benralizumab binds to the &#x003b1; subunit of the interleukin-5 receptor, decreasing eosinophil activation.&#x000a0;Benralizumab also decreases antibody-dependent cell-mediated cytotoxicity.<xref ref-type="bibr" rid="article-17921.r23">[23]</xref></p>
        <p><bold>Anti-interleukin-4 receptor &#x003b1; monoclonal antibody:</bold>&#x000a0;Dupilumab is an IgG4 antibody that inhibits IL-4 and IL-13 signaling by binding to the IL-4R &#x003b1; subunit, inhibiting the&#x000a0;release of proinflammatory cytokines and chemokines.<xref ref-type="bibr" rid="article-17921.r24">[24]</xref></p>
        <p><bold>Immunotherapy:</bold>&#x000a0;Subcutaneous immunotherapy (SCIT) for asthma is the administration of specific exogenous aeroallergens with demonstrated sensitivity. Prerequisites are documented hypersensitivity to the specific allergen by skin testing (after 15 to 20 minutes) and antigen-specific IgE antibodies in a blood sample.<xref ref-type="bibr" rid="article-17921.r25">[25]</xref></p>
      </sec>
      <sec id="article-17921.s3" sec-type="Function">
        <title>Function</title>
        <p>
<bold>Essential Components of Management of Asthma in the Pediatric Population</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diagnosis of asthma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Stepwise approach for management of asthma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Emphasis on the use of preferred&#x000a0;treatment at&#x000a0;each step</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>SMART (single maintenance and reliever therapy) before proceeding to a higher-step level of treatment.<xref ref-type="bibr" rid="article-17921.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Achieve adequate symptom control</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Management of asthma exacerbation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Minimize&#x000a0;adverse drug reactions</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Shared decision-making&#x000a0;accounting for&#x000a0;risks vs. benefits and personal preferences</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patient education&#x000a0;regarding inhaler techniques</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Improving patient adherence</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Assessment of environmental triggers</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Evaluation&#x000a0;and management of comorbidities</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Overall reduction in mortality</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Assessment of quality of life by using a validated questionnaire (Pediatric Asthma Quality of Life Questionnaire)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consultation with a pulmonologist/immunologist if the patient requires care at step 3 or higher.<xref ref-type="bibr" rid="article-17921.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>According to&#x000a0;NAEPPCC (National Asthma Education and Prevention Program Coordinating Committee) and&#x000a0;NHLBI (National Heart, Lung, and Blood Institute), treatment regimens&#x000a0;by age group are described below.&#x000a0;The following section highlights a stepwise approach to asthma medications used for rescue and control. Step therapy is based on the domains of severity and control.<xref ref-type="bibr" rid="article-17921.r28">[28]</xref></p>
        <p>
<bold>Asthma Management in the Age Group&#x000a0;0 to 4 years</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 1:</bold> The preferred therapy is PRN SABA (short-acting &#x003b2;2-agonist). In patients with recurrent wheezing, a short (7 to 10 days) course of ICS with PRN&#x000a0;SABA is recommended at the onset of respiratory tract infection. The&#x000a0;strategy of initiating ICS and PRN SABA decreases asthma exacerbations and reduces&#x000a0;the use of&#x000a0;systemic corticosteroids.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 2:</bold>&#x000a0;Daily low-dose ICS (inhaled corticosteroids) as controller therapy and PRN SABA as quick relief therapy. An alternative regimen is daily montelukast or cromolyn and PRN SABA.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 3:</bold> Daily medium dose ICS as controller therapy and PRN SABA for quick relief therapy.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 4:</bold>&#x000a0;Daily medium dose ICS-LABA (long-acting &#x003b2;2-agonist) as controller therapy and PRN SABA for quick relief therapy. The alternative regimen is a daily medium dose of ICS + montelukast and PRN SABA.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 5:</bold>&#x000a0;Daily high-dose ICS-LABA as controller therapy and PRN SABA for&#x000a0;quick relief therapy. The alternative regimen is a daily&#x000a0;high dose of ICS + montelukast and PRN SABA.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 6:</bold> Daily high-dose ICS-LABA + oral systemic corticosteroid and PRN SABA. The alternative regimen is daily high-dose ICS + montelukast + oral systemic corticosteroid and PRN SABA.</p>
          </list-item>
        </list>
        <p>Albuterol (salbutamol) or levalbuterol is the preferred drug for SABA. LABA&#x000a0;medications are formoterol and salmeterol, with formoterol being the preferred drug. Inhaled corticosteroids (ICS) are budesonide, beclomethasone, and fluticasone.<xref ref-type="bibr" rid="article-17921.r29">[29]</xref> The most commonly used&#x000a0;combination&#x000a0;is&#x000a0;ICS and formoterol, preferably in a single inhaler.&#x000a0;FDA has issued a boxed warning for montelukast due to&#x000a0;neuropsychiatric adverse events.<xref ref-type="bibr" rid="article-17921.r30">[30]</xref>&#x000a0;Reassess the patient in 4 to 6 weeks and step up if required. The clinician can consider stepping down therapy for patients with well-controlled asthma for &#x0003e;&#x000a0;3 consecutive months.</p>
        <p>
<bold>Asthma Management in the Age Group 5 to 11 years</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 1:</bold>&#x000a0;PRN SABA</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 2:</bold> Daily low-dose ICS as controller therapy&#x000a0;and&#x000a0;PRN SABA as quick relief therapy. Daily therapy with LTRA, cromolyn, nedocromil, theophylline, and&#x000a0;PRN SABA are alternative regimens.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 3:</bold>&#x000a0;Daily&#x000a0;combination of low-dose&#x000a0;ICS-formoterol as controller and quick relief therapy. The alternative&#x000a0;regimen is daily medium-dose&#x000a0;ICS and PRN SABA. Another alternative regimen is daily low-dose&#x000a0;ICS-LABA, daily low-dose&#x000a0;ICS + LTRA, or daily low-dose ICS + theophylline and PRN SABA.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 4:</bold>&#x000a0;Daily combination of&#x000a0;medium-dose&#x000a0;ICS-formoterol as controller therapy and medium-dose&#x000a0;ICS-formoterol PRN for&#x000a0;quick relief therapy. The alternative regimen is a daily medium dose of ICS-LABA as controller therapy and PRN SABA as quick relief therapy. Another alternative regimen is daily medium dose&#x000a0;ICS + LTRA or daily medium dose&#x000a0;ICS + theophylline as controller therapy and PRN SABA as quick relief therapy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 5:</bold>&#x000a0;Daily high-dose ICS-LABA as controller therapy and PRN SABA for&#x000a0;quick relief therapy. An alternative regimen is a daily&#x000a0;high dose of ICS + LTRA and PRN SABA. Another alternative regimen is daily high-dose ICS + theophylline and PRN SABA.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 6:</bold> Daily high-dose ICS-LABA + oral systemic corticosteroid as controller therapy and PRN SABA. An alternative regimen is daily high-dose ICS + LTRA + oral systemic corticosteroid and PRN SABA. Another alternative regimen of daily high-dose ICS + theophylline + oral systemic corticosteroid and PRN SABA</p>
          </list-item>
        </list>
        <p>For Steps 2 to 4, there is a subcutaneous&#x000a0;immunotherapy as an adjunct therapy to standard&#x000a0;treatment in&#x000a0;patients &#x02265; 5 years of age. Subcutaneous immunotherapy (SCIT) is recommended as an adjunct treatment for&#x000a0;patients&#x000a0;with&#x000a0;established allergic sensitization and evidence of worsening asthma symptoms&#x000a0;following exposure&#x000a0;to the relevant antigens.<xref ref-type="bibr" rid="article-17921.r31">[31]</xref></p>
        <p>For Steps 5 and 6, omalizumab, an&#x000a0;anti-immunoglobulin E (IgE) monoclonal antibody, should be considered; other biologic therapies are not FDA-approved for the age group 5 to 11 years.<xref ref-type="bibr" rid="article-17921.r32">[32]</xref></p>
        <p>FDA age ranges for infancy are birth&#x000a0;to&#x000a0;2 years; childhood, 2 to 12 years; and adolescence, from 12 to 21.<xref ref-type="bibr" rid="article-17921.r33">[33]</xref>&#x000a0;This review also includes asthma management in the adolescent age group.</p>
        <p>
<bold>Asthma Management for Ages &#x0003e;12 years</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 1:</bold>&#x000a0;PRN SABA</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 2:</bold> Daily low-dose ICS&#x000a0;and PRN SABA&#x000a0;or&#x000a0;PRN concomitant&#x000a0;ICS and SABA. An alternative regimen is daily LTRA and&#x000a0;PRN SABA. An additional alternative&#x000a0;regimen&#x000a0;is cromolyn or nedocromil or zileuton or theophylline and&#x000a0;PRN SABA (less preferred&#x000a0;for use in the&#x000a0;United States due to potential adverse drug reactions).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 3:</bold> Daily and PRN&#x000a0;combination&#x000a0;low-dose ICS-formoterol. The alternative strategy is daily medium-dose&#x000a0;ICS and PRN&#x000a0;SABA. An alternative regimen is daily low-dose&#x000a0;ICS + (LABA/LAMA/LTRA) and PRN SABA. LAMA is a long-acting muscarinic antagonist like tiotropium.<xref ref-type="bibr" rid="article-17921.r34">[34]</xref>&#x000a0;The optional&#x000a0;regimen is daily low-dose ICS&#x000a0;+ theophylline or zileuton and&#x000a0;PRN SABA (less preferred&#x000a0;for use in the&#x000a0;US due to potential adverse drug reactions).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 4:</bold> Daily and PRN&#x000a0;combination&#x000a0;medium-dose&#x000a0;ICS-formoterol. The alternative regimen is daily medium-dose ICS-LABA or medium-dose ICS + LAMA and&#x000a0;PRN SABA. The optional regimen is daily medium dose&#x000a0;ICS + (LTRA or theophylline or zileuton) and PRN SABA (less preferred&#x000a0;for use in the US due to potential adverse drug reactions).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 5:</bold> Daily medium to high&#x000a0;dose ICS-LABA combination +&#x000a0;LAMA and&#x000a0;PRN SABA. The alternative regimen is medium to high&#x000a0;dose ICS-LABA&#x000a0;or daily high-dose&#x000a0;ICS + LTRA and&#x000a0;PRN SABA.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Step 6:</bold> Daily high-dose&#x000a0;ICS-LABA +&#x000a0;oral systemic&#x000a0;corticosteroids +&#x000a0;PRN SABA.</p>
          </list-item>
        </list>
        <p>For steps 2 to 4, subcutaneous immunotherapy (SCIT) is recommended for patients &#x0003e;5 years of age, as described above.&#x000a0;</p>
        <p>For Steps 5 and 6, biologics may be considered&#x000a0;(e.g., anti-IgE, anti-IL4, anti-IL13, anti-IL5, anti-IL5R).<xref ref-type="bibr" rid="article-17921.r35">[35]</xref>&#x000a0;However, no&#x000a0;specific recommendations&#x000a0;have been made. Consultation with an asthma specialist or immunologist is recommended.&#x000a0;</p>
        <p>
<bold>SMART (Single Maintenance and Reliever Therapy)</bold>
</p>
        <p>The SMART approach is a treatment with ICS and LABA (formoterol) for daily and rescue treatment. It is advised as the choice of therapy for&#x000a0;patients&#x000a0;&#x02265;&#x000a0;4 years (not well-controlled on a low- or medium-dose daily ICS alone). Formoterol is the LABA of choice because it has a rapid onset of action and can be used more than twice daily. SMART is a technique for decreasing exacerbation and&#x000a0;total corticosteroid use. There&#x000a0;is&#x000a0;a lower risk of growth suppression&#x000a0;in patients&#x000a0;taking SMART versus daily higher-dose ICS treatment. Consequently, patients with uncontrolled asthma on daily ICS-LABA maintenance therapy should be considered for&#x000a0;SMART before moving to a higher-step level of treatment.<xref ref-type="bibr" rid="article-17921.r26">[26]</xref></p>
        <p>
<bold>Clinical Utility of FeNO Testing</bold>
</p>
        <p>Nitric oxide can be calculated in exhaled breath and estimate the level of airway&#x000a0;inflammation. In individuals with asthma, fractional exhaled nitric oxide (FeNO) is&#x000a0;a useful&#x000a0;indicator of airway type 2 bronchial or eosinophilic inflammation. FeNO is a quantitative, noninvasive, straightforward, and safe technique for estimating airway inflammation. In patients&#x000a0;ages&#x000a0;5 years and older diagnosed with asthma after extensive evaluation,&#x000a0;FeNO measurement can help as an adjunct to the&#x000a0;diagnosis and response to therapy. It is&#x000a0;particularly&#x000a0;useful in patients whose&#x000a0;spirometry testing cannot be performed accurately. FeNO levels &#x0003e; 50 ppb in adults or FeNO levels&#x000a0;&#x0003e;&#x000a0;35 ppb in children aged 5 to 12 years are&#x000a0;consistent with T2 inflammation, and&#x000a0;these patients are more likely to respond to corticosteroid treatment. ATS (The American Thoracic Society) clinical practice guidelines also endorse FeNO as an adjunct for diagnosis and determining the probability of corticosteroid responsiveness.<xref ref-type="bibr" rid="article-17921.r36">[36]</xref></p>
      </sec>
      <sec id="article-17921.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Adverse Drug Reactions (ADR)</bold>
</p>
        <p><bold>Inhaled &#x003b2;-2 agonist:</bold> Common adverse drug reactions of SABA and LABA include tremors, tachycardia, and palpitations. These adverse effects are seen more often during initial exposure.<xref ref-type="bibr" rid="article-17921.r37">[37]</xref>&#x000a0;A boxed warning advises that long-acting &#x003b2;-2 agonists such as salmeterol or formoterol without ICS increase the risk of asthma-related death.</p>
        <p><bold>Inhaled corticosteroids:</bold> Oropharyngeal candidiasis and dysphonia are the most&#x000a0;commonly&#x000a0;documented ICS-associated ADR. Using a spacer device and rinsing the mouth after using an ICS decreases the risk of oral thrush.<xref ref-type="bibr" rid="article-17921.r38">[38]</xref></p>
        <p><bold>Long-acting muscarinic antagonist:</bold> The anticholinergic adverse effects of LAMA (tiotropium)&#x000a0;are dry mouth, constipation, blurring of vision, and urinary difficulty or retention.<xref ref-type="bibr" rid="article-17921.r39">[39]</xref></p>
        <p><bold>Systemic corticosteroids:</bold>&#x000a0;Vomiting, behavioral changes, sleep disturbance, and increased risk of infections are common with short-course oral corticosteroids in children.<xref ref-type="bibr" rid="article-17921.r40">[40]</xref>&#x000a0;Long-term&#x000a0;ADR of systemic corticosteroids includes osteoporosis, diabetes, adrenal insufficiency, delayed wound healing, cataracts, aseptic joint necrosis,&#x000a0;GI bleeding, and growth suppression.<xref ref-type="bibr" rid="article-17921.r41">[41]</xref><xref ref-type="bibr" rid="article-17921.r42">[42]</xref><xref ref-type="bibr" rid="article-17921.r43">[43]</xref></p>
        <p><bold>Leukotriene receptor antagonist:</bold> The most serious adverse event associated with montelukast therapy is neuropsychiatric adverse effects (FDA boxed warning). Neuropsychiatric&#x000a0;ADR ranges from insomnia to suicidal ideation.<xref ref-type="bibr" rid="article-17921.r2">[2]</xref><xref ref-type="bibr" rid="article-17921.r30">[30]</xref>&#x000a0;Zafirlukast is associated with hepatotoxicity.<xref ref-type="bibr" rid="article-17921.r44">[44]</xref></p>
        <p><bold>Mast cell stabilizers:</bold> Mast cell stabilizers used in asthma are cromolyn and nedocromil.<xref ref-type="bibr" rid="article-17921.r18">[18]</xref>&#x000a0;Adverse effects associated with cromolyn may include throat irritation, sneezing, and an unpleasant taste.<xref ref-type="bibr" rid="article-17921.r45">[45]</xref>&#x000a0;ADR due to nedocromil&#x000a0;are an unpleasant taste, headache, and cough.<xref ref-type="bibr" rid="article-17921.r46">[46]</xref></p>
        <p><bold>Theophylline:</bold> Common adverse drug reactions include nausea, vomiting, and headaches. At higher concentrations, seizures and cardiac arrhythmias, including&#x000a0;multifocal atrial tachycardia, have been reported.<xref ref-type="bibr" rid="article-17921.r47">[47]</xref><xref ref-type="bibr" rid="article-17921.r20">[20]</xref></p>
        <p><bold>Omalizumab:</bold> The most common adverse effect is skin inflammation at the injection site. A potentially life-threatening and rare adverse drug reaction&#x000a0;is anaphylaxis.<xref ref-type="bibr" rid="article-17921.r48">[48]</xref></p>
        <p><bold>Dupilumab:</bold> Common ADR are mild injection site reactions and eosinophilia.</p>
        <p><bold>Mepolizumab:</bold>&#x000a0;Headache and bronchitis are common.</p>
        <p><bold>Benralizumab:</bold> ADR associated with are headache, fever, nasopharyngitis, and sinusitis.<xref ref-type="bibr" rid="article-17921.r2">[2]</xref></p>
        <p><bold>Subcutaneous immunotherapy (SCIT):</bold> SCIT should be administered under direct supervision&#x000a0;due to the potential for anaphylaxis, urticaria, rhinitis, nausea, diarrhea, vomiting, hypotension, and arrhythmias. Consequently, a 30-minute observational period&#x000a0;is needed after&#x000a0;each SCIT injection.<xref ref-type="bibr" rid="article-17921.r6">[6]</xref></p>
        <p>
<bold>Asthma Phenotype</bold>
</p>
        <p>Global Initiative for Asthma (GINA) guidelines show that population-level recommendations depend on type II or non-type II phenotypes. Type II inflammation is found in patients with severe asthma and atopy. It is associated with allergic conditions such as nasal polyposis and atopic dermatitis. Elevated serum, sputum eosinophils, and increased FeNO characterize type 2 inflammation. Management includes optimal use of ICS and targeted biologics. Dupilumab is indicated in patients with&#x000a0;severe&#x000a0;eosinophilia or type 2 asthma uncontrolled on high-dose ICS-LABA. Pediatric patients with persistently elevated IgE levels&#x000a0;respond well to omalizumab.<xref ref-type="bibr" rid="article-17921.r49">[49]</xref><xref ref-type="bibr" rid="article-17921.r7">[7]</xref></p>
        <p>
<bold>Inadequate Control</bold>
</p>
        <p>Increased&#x000a0;use of albuterol (salbutamol) for &#x0003e;2 days a week for symptom relief typically indicates inadequate control and may require a step-up in treatment.</p>
        <p>
<bold>Inhaler Technique</bold>
</p>
        <p>A systemic review concluded that using&#x000a0;turbuhaler and diskus inhalers is better than metered-dose inhalers (MDI) in children. The best technique is when MDIs are used with spacers. Consequently, pressured MDI with a spacer is the preferred device in children. Different-sized masks are available. A valved holding chamber&#x000a0;enables the&#x000a0;diffusion of medication&#x000a0;and&#x000a0;the coordination of actuation. A nebulizer with a facemask or mouthpiece&#x000a0;is effective in children who cannot be taught how to use a spacer device. Not every medication is available as a nebulizer agent.<xref ref-type="bibr" rid="article-17921.r50">[50]</xref><bold>&#x000a0;</bold></p>
        <p>
<bold>Compliance to Pharmacotherapy</bold>
</p>
        <p>Inadequate adherence in children with asthma is a&#x000a0;leading cause of asthma attacks and a factor in asthma deaths. Subjective and objective measures for monitoring compliance have limitations; electronic monitoring devices (EMDs) can be considered.<xref ref-type="bibr" rid="article-17921.r51">[51]</xref></p>
        <p>
<bold>Asthma Exacerbation&#x000a0;</bold>
</p>
        <p>In severe cases, management of exacerbations includes&#x000a0;bronchodilators, oxygen therapy, glucocorticosteroids, and mechanical ventilation. Adding a LAMA (tiotropium) to ICS-LABA for&#x000a0;patients with uncontrolled asthma on ICS-LABA enhances asthma control. Systemic corticosteroids may still be required depending on the patient's presentation.</p>
        <p>In young children, suspension is better tolerated and accepted than tablets. In addition, for children aged 0 to 4 years with a history of previous severe exacerbations, a short course of oral systemic corticosteroids is advised.&#x000a0;Frequent exacerbations requiring oral steroids&#x000a0;indicate inadequate&#x000a0;asthma control and should require a review of maintenance therapy.<xref ref-type="bibr" rid="article-17921.r2">[2]</xref></p>
        <p>
<bold>FeNO Testing and Pharmacotherapy</bold>
</p>
        <p>FeNO can be conducted in primary care settings and predict corticosteroid response.&#x000a0;FeNO testing is not a replacement for standard&#x000a0;assessment&#x000a0;and should not be used in isolation to estimate disease&#x000a0;activity and forecast future exacerbation. In addition, the costs associated with equipment and supply can restrict the utility&#x000a0;of FeNO&#x000a0;in the primary care office setting. Moreover, analysis requires experienced immunologists or pulmonologists to interpret the results. According to&#x000a0;NHLBI guidelines,&#x000a0;ICS should not be&#x000a0;stopped only based on low FeNO levels.<xref ref-type="bibr" rid="article-17921.r6">[6]</xref></p>
        <p>
<bold>Comorbidities</bold>
</p>
        <p>Comorbidities such as chronic rhinosinusitis, obesity,&#x000a0;gastroesophageal&#x000a0;reflux&#x000a0;disease (GERD), and&#x000a0;obstructive sleep apnea&#x000a0;are associated with&#x000a0;flare-ups and poor quality of life.&#x000a0;Treatment&#x000a0;of comorbid conditions is essential; however, management can complicate treatment adherence and asthma control due to polypharmacy.<xref ref-type="bibr" rid="article-17921.r52">[52]</xref></p>
        <p>
<bold>Bronchial Thermoplasty (BT)</bold>
</p>
        <p>Bronchial thermoplasty&#x000a0;has not been extensively evaluated in pediatric patients;&#x000a0;consequently,&#x000a0;BT is not recommended in children.<xref ref-type="bibr" rid="article-17921.r53">[53]</xref></p>
        <p>
<bold>Peak Expiratory Flow (PEF) and Spirometry </bold>
</p>
        <p>PEF and spirometry are commonly used to estimate airflow obstruction and reversibility. GINA suggests the use of PEF or spirometry in the diagnosis of asthma in children aged over&#x000a0;5. However, EF and spirometry are not feasible in children aged 1 to 4 years.</p>
        <p>
<bold>Asthma Action Plans</bold>
</p>
        <p>An asthma action plan (AAP) is a&#x000a0;written&#x000a0;document&#x000a0;in which the family or caregiver&#x000a0;is&#x000a0;provided with up-to-date instructions regarding daily asthma&#x000a0;medications, symptoms that show asthma control deterioration, response when these symptoms are identified, and steps in the case of an emergency.<xref ref-type="bibr" rid="article-17921.r54">[54]</xref><xref ref-type="bibr" rid="article-17921.r55">[55]</xref><xref ref-type="bibr" rid="article-17921.r56">[56]</xref>&#x000a0;The caregivers must be confident and careful when using the asthma action plan, as they must decide on initiating treatment at the onset of deterioration. A recent study indicated that a pictographic asthma action plan could be helpful for caregivers with low health literacy.<xref ref-type="bibr" rid="article-17921.r57">[57]</xref></p>
        <p>
<bold>Quality of Life</bold>
</p>
        <p>Quality of life is significantly compromised in children with uncontrolled asthma. Standardized questionnaires such as the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) should be used to evaluate the quality of life. A study showed that although pharmacotherapy can improve quality of life, the emotional&#x000a0;domain&#x000a0;is not addressed. Psychosocial&#x000a0;support&#x000a0;is needed in addition to standard pharmacotherapy.<xref ref-type="bibr" rid="article-17921.r58">[58]</xref></p>
      </sec>
      <sec id="article-17921.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Asthma is a serious health and economic concern in the United States, costing $56 billion yearly. Uncontrolled asthma disrupts daily life and causes&#x000a0;1 in&#x000a0;2 children to miss at least&#x000a0;1 day of school. This&#x000a0;caused about 10.5 million missed school days.<xref ref-type="bibr" rid="article-17921.r59">[59]</xref><xref ref-type="bibr" rid="article-17921.r60">[60]</xref><xref ref-type="bibr" rid="article-17921.r61">[61]</xref>&#x000a0;According to the CDC report, in 2021, the percentage of children aged under 18 years who currently have asthma is 6.5%.</p>
        <p>The number of emergency department visits for asthma is approximately 1.2 million.&#x000a0;From 2016 to 2018, the estimated prevalence of asthma was about 8.1% in children aged 0 to 17 years.&#x000a0;From 2016 to 2018, children with asthma&#x000a0;had significantly more emergency department and urgent care visits (17.9%) than adults (10.1%).&#x000a0;</p>
        <p>In the context of the COVID-19 pandemic, it is essential to remember that CDC has recognized asthma as a risk factor for severe COVID-19.<xref ref-type="bibr" rid="article-17921.r62">[62]</xref>&#x000a0;In patients with severe asthma using biologic therapy,&#x000a0;the vaccine and the&#x000a0;biologics should not be administered on the same day.<xref ref-type="bibr" rid="article-17921.r63">[63]</xref>&#x000a0;Optimal use of pharmacotherapy according to guidelines, use of a step-wise&#x000a0;approach, and assessment of compliance and control at each visit can significantly reduce the morbidity, mortality, emergency room visits, and healthcare costs associated with asthma. Clinicians should also emphasize using preferred therapy at each step to optimize pharmacotherapy and minimize ADR.<xref ref-type="bibr" rid="article-17921.r64">[64]</xref></p>
      </sec>
      <sec id="article-17921.s6" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>SABA overuse has been associated with increased risks of exacerbation. Long-term use of &#x003b2;-2 agonists has been associated with ischemia, heart failure, arrhythmias, and risk of sudden death.<xref ref-type="bibr" rid="article-17921.r65">[65]</xref>&#x000a0;A high dose of ICS is associated with systemic ADR due to increased absorption. It may increase the risk of adrenal suppression, cataracts, glaucoma, psychiatric effects, and risk of infection.<xref ref-type="bibr" rid="article-17921.r66">[66]</xref>&#x000a0;</p>
        <p>Patients&#x000a0;on chronic systemic steroids for asthma have a suppression of the hypothalamic-pituitary-adrenal (HPA) axis. A sudden withdrawal of steroids can result in adrenal insufficiency. Steroid withdrawal syndrome is marked by malaise, postural hypotension, generalized weakness, arthralgia, headaches, mood swings, and emotional lability and can be life-threatening if not recognized promptly. A gradual steroid taper is recommended.<xref ref-type="bibr" rid="article-17921.r67">[67]</xref>&#x000a0;</p>
        <p>Theophylline has a narrow therapeutic index. Theophylline toxicity presents with hypotension, cardiac arrhythmias, and seizures. Hypotension requires aggressive fluid resuscitation and vasopressors.&#x000a0;IV benzodiazepines are used for seizures. Phenobarbital is used for refractory seizures. In a life-threatening overdose, hemodialysis is indicated.<xref ref-type="bibr" rid="article-17921.r68">[68]</xref>&#x000a0;Omalizumab is associated with rare cases of anaphylaxis. Dupilumab is associated with rare cases of eosinophilic granulomatosis with polyangiitis. (EGPA or Churg-Strauss Syndrome).<xref ref-type="bibr" rid="article-17921.r7">[7]</xref><xref ref-type="bibr" rid="article-17921.r69">[69]</xref></p>
      </sec>
      <sec id="article-17921.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of asthma in children are complex. Asthma management involves a multi-faceted approach, including medication, education, skills training, clinical monitoring, and environmental control measures when necessary. The goals of asthma management include&#x000a0;enhanced quality of life, control of asthma symptoms, and&#x000a0;minimized&#x000a0;risks from exacerbations and medication side effects.<xref ref-type="bibr" rid="article-17921.r70">[70]</xref>&#x000a0;</p>
        <p>Pediatricians usually prescribe medications for asthma in children. Immunologists or asthma specialists should be consulted at the&#x000a0;appropriate&#x000a0;step for using&#x000a0;novel biologic therapies. Pharmacists should verify dosing, check for interactions, and ensure medication reconciliation. Pediatric nurses should monitor growth and adverse effects at every visit.&#x000a0;Admission to the PICU (pediatric intensive care unit) or neonatal intensive&#x000a0;care unit (NICU) may be&#x000a0;required for severe asthma exacerbation. Pediatric hospitalists, pulmonologists, and neonatologists are crucial in managing severe asthma exacerbation and management complications.</p>
        <p>In case of toxicity, consultation with a medical toxicologist may be essential.&#x000a0;The interprofessional approach&#x000a0;from clinicians (MD, DO, NP, PA), toxicologists, pediatric pharmacists, respiratory therapists, and specialty-trained nurses improves the treatment efficacy and optimizes the outcomes&#x000a0;in the treatment of pediatric asthma.&#x000a0;</p>
      </sec>
      <sec id="article-17921.s8" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>Nursing interventions and actions</p>
        <list list-type="bullet">
          <list-item>
            <p>Checking pulse oximetry</p>
          </list-item>
          <list-item>
            <p>Monitor the vitals</p>
          </list-item>
          <list-item>
            <p>Provide oxygen if O<sub>2</sub> saturation is less than 90%
<list list-type="bullet"><list-item><p>Start at 2 liters nasal cannula</p></list-item><list-item><p>Increase as needed</p></list-item><list-item><p>Consult the provider and respiratory therapist if more than 6 liters of nasal cannula is required.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Evaluate the patient to determine if they are receiving&#x000a0;adequate&#x000a0;oxygen.</p>
          </list-item>
          <list-item>
            <p>Learn triggers and ensure the room does not have any, ie, flowers, dust, animal dander, wool blankets, etc.</p>
          </list-item>
          <list-item>
            <p>Ensure&#x000a0;proper delivery of medications by nebulization</p>
          </list-item>
          <list-item>
            <p>Patient education about&#x000a0;ADR and adequate use of MDI to prevent oral candidiasis.<xref ref-type="bibr" rid="article-17921.r71">[71]</xref></p>
          </list-item>
          <list-item>
            <p>Physical therapists play an essential role in improving lung function. A study has demonstrated that physical therapy can improve&#x000a0;forced vital capacity (FVC).<xref ref-type="bibr" rid="article-17921.r72">[72]</xref></p>
          </list-item>
          <list-item>
            <p>Respiratory therapist-guided bronchodilator weaning based on the MPIS (modified pulmonary index score) can reduce the&#x000a0;hospital length of stay (LOS).<xref ref-type="bibr" rid="article-17921.r73">[73]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17921.s9" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>Nursing monitoring should include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Auscultate lung sounds
<list list-type="bullet"><list-item><p>If wheezing, they may need a breathing treatment.</p></list-item><list-item><p>No breath sounds (silent chest) or stridor is usually ominous signs and require immediate reporting to the team leader.</p></list-item><list-item><p>Crackles may have pneumonia and may need suctioning.<xref ref-type="bibr" rid="article-17921.r74">[74]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Positioning the patient in an upright position</p>
          </list-item>
          <list-item>
            <p>Obtain a baseline peak flow and monitor for the decline. The smaller the number, the less amount of air they are moving.</p>
          </list-item>
          <list-item>
            <p>Complete prescribed breathing treatments such as albuterol for bronchodilation and&#x000a0;tiotropium to decrease bronchospasm.</p>
          </list-item>
          <list-item>
            <p>Monitor the adverse drug reactions of corticosteroids.</p>
          </list-item>
          <list-item>
            <p>If theophylline is prescribed,&#x000a0;consider&#x000a0;therapeutic drug monitoring to prevent toxicity.<xref ref-type="bibr" rid="article-17921.r75">[75]</xref></p>
          </list-item>
          <list-item>
            <p>Make sure the entire medical team is aware if the patient is getting worse; know the location of the crash cart.</p>
          </list-item>
        </list>
        <p>If the nursing&#x000a0;or allied health staff thinks the patient is deteriorating or airway closure may be imminent, it is better to be proactive than reactive. Contact the medical team&#x000a0;immediately.<xref ref-type="bibr" rid="article-17921.r76">[76]</xref></p>
      </sec>
      <sec id="article-17921.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17921&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17921">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17921/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17921">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17921.s11">
        <title>References</title>
        <ref id="article-17921.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Asthma guidelines: the Global Initiative for Asthma in relation to national guidelines.</article-title>
            <source>Curr Opin Allergy Clin Immunol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-103</page-range>
            <pub-id pub-id-type="pmid">28118238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Townshend</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brodlie</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of asthma in children.</article-title>
            <source>BMJ Paediatr Open</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">35648804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Cicco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peroni</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Ragazzo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Comberiati</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Application of exhaled nitric oxide (FeNO) in pediatric asthma.</article-title>
            <source>Curr Opin Allergy Clin Immunol</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>151</fpage>
            <page-range>151-158</page-range>
            <pub-id pub-id-type="pmid">33620882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gruber</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>McKee-Huger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Byerly</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Raczkowski</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Removing asthma triggers and improving children's health: The Asthma Partnership Demonstration project.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2016</year>
            <month>May</month>
            <volume>116</volume>
            <issue>5</issue>
            <fpage>408</fpage>
            <page-range>408-14</page-range>
            <pub-id pub-id-type="pmid">27153740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maciag</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Phipatanakul</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Preventing the development of asthma: stopping the allergic march.</article-title>
            <source>Curr Opin Allergy Clin Immunol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-168</page-range>
            <pub-id pub-id-type="pmid">30507718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC)</collab>
              <name>
                <surname>Cloutier</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Baptist</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Blake</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Bryant-Stephens</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>DiMango</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Elward</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Hartert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lemanske</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Ouellette</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Pace</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Schatz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Skolnik</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Stout</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Teach</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Umscheid</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>2020 Focused Updates to the Asthma Management Guidelines: A&#x000a0;Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>146</volume>
            <issue>6</issue>
            <fpage>1217</fpage>
            <page-range>1217-1270</page-range>
            <pub-id pub-id-type="pmid">33280709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddel</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Bacharier</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Bateman</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Brightling</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Brusselle</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Buhl</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Duijts</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Drazen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mortimer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pitrez</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yorgancioglu</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Boulet</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>205</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-35</page-range>
            <pub-id pub-id-type="pmid">34658302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silva</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jacinto</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Inhaled &#x003b2;<sub>2</sub>-agonists in asthma management: an evolving story.</article-title>
            <source>Breathe (Sheff)</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>375</fpage>
            <page-range>375-377</page-range>
            <pub-id pub-id-type="pmid">28210324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cates</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wieland</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Oleszczuk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kew</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Feb</month>
            <day>06</day>
            <volume>2014</volume>
            <issue>2</issue>
            <fpage>CD010314</fpage>
            <pub-id pub-id-type="pmid">24504983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ridha</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>B&#x000e9;dard</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Smyrnova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drouin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pruteanu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Essouri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ducharme</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Tiotropium bromide as adjunct therapy in children with asthma: a clinical experience.</article-title>
            <source>Allergy Asthma Clin Immunol</source>
            <year>2021</year>
            <month>Dec</month>
            <day>12</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <pub-id pub-id-type="pmid">34895321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daley-Yates</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Inhaled corticosteroids: potency, dose equivalence and therapeutic index.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>372</fpage>
            <page-range>372-80</page-range>
            <pub-id pub-id-type="pmid">25808113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hossny</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rosario</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>El-Ghoneimy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Soh</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Le Souef</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The use of inhaled corticosteroids in pediatric asthma: update.</article-title>
            <source>World Allergy Organ J</source>
            <year>2016</year>
            <volume>9</volume>
            <fpage>26</fpage>
            <pub-id pub-id-type="pmid">27551328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoefgen</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kercsmar</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Murtagh-Kurowski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Forton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Auger</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Dexamethasone Versus Prednisone in Children Hospitalized With Asthma Exacerbation.</article-title>
            <source>Hosp Pediatr</source>
            <year>2022</year>
            <month>Mar</month>
            <day>01</day>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-335</page-range>
            <pub-id pub-id-type="pmid">35128557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowe</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Edmonds</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Spooner</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Diner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Camargo</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroid therapy for acute asthma.</article-title>
            <source>Respir Med</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>275</fpage>
            <page-range>275-84</page-range>
            <pub-id pub-id-type="pmid">15072167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nayak</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A review of montelukast in the treatment of asthma and allergic rhinitis.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>679</fpage>
            <page-range>679-86</page-range>
            <pub-id pub-id-type="pmid">15013935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Montelukast use over the past 20 years: monitoring of its effects and safety issues.</article-title>
            <source>Clin Exp Pediatr</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>63</volume>
            <issue>10</issue>
            <fpage>376</fpage>
            <page-range>376-381</page-range>
            <pub-id pub-id-type="pmid">32023405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pergola</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koeberle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dehm</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bramanti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cuzzocrea</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Werz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sautebin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.</article-title>
            <source>Br J Pharmacol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>161</volume>
            <issue>3</issue>
            <fpage>555</fpage>
            <page-range>555-70</page-range>
            <pub-id pub-id-type="pmid">20880396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finn</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Twenty-first century mast cell stabilizers.</article-title>
            <source>Br J Pharmacol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>170</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-37</page-range>
            <pub-id pub-id-type="pmid">23441583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Speight</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Sodium cromoglycate (cromolyn sodium): a review of its mode of action, pharmacology, therapeutic efficacy and use.</article-title>
            <source>Drugs</source>
            <year>1974</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>164</fpage>
            <page-range>164-282</page-range>
            <pub-id pub-id-type="pmid">4212341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Theophylline.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>188</volume>
            <issue>8</issue>
            <fpage>901</fpage>
            <page-range>901-6</page-range>
            <pub-id pub-id-type="pmid">23672674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chipps</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Lanier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Milgrom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Deschildre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hedlin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Szefler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kattan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kianifard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Haselkorn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ros&#x000e9;n</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Trzaskoma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Busse</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2017</year>
            <month>May</month>
            <volume>139</volume>
            <issue>5</issue>
            <fpage>1431</fpage>
            <page-range>1431-1444</page-range>
            <pub-id pub-id-type="pmid">28477722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pavord</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Menzies-Gow</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buhl</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chanez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dransfield</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lugogo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Keene</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Bradford</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Yancey</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>1121</fpage>
            <page-range>1121-1132.e7</page-range>
            <pub-id pub-id-type="pmid">32889223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Canonica</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Chanez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Menzella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Louis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cosio</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Lugogo</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burden</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garcia Gil</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.</article-title>
            <source>Allergy</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>150</fpage>
            <page-range>150-161</page-range>
            <pub-id pub-id-type="pmid">33978983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Corren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pavord</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Maspero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wenzel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rabe</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Busse</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Katelaris</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tohda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Staudinger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pirozzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ruddy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akinlade</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martincova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>NMH</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Teper</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Jun</month>
            <day>28</day>
            <volume>378</volume>
            <issue>26</issue>
            <fpage>2486</fpage>
            <page-range>2486-2496</page-range>
            <pub-id pub-id-type="pmid">29782217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parashar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pandya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Portnoy</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Pediatric subcutaneous allergen immunotherapy.</article-title>
            <source>Allergy Asthma Proc</source>
            <year>2022</year>
            <month>Jul</month>
            <day>01</day>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>286</fpage>
            <page-range>286-291</page-range>
            <pub-id pub-id-type="pmid">35818145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cloutier</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Teach</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lemanske</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Blake</surname>
                <given-names>KV</given-names>
              </name>
            </person-group>
            <article-title>The 2020 Focused Updates to the NIH Asthma Management Guidelines: Key Points for Pediatricians.</article-title>
            <source>Pediatrics</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>147</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">33941586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pade</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Agnihotri</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Vangala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Okelo</surname>
                <given-names>SO</given-names>
              </name>
            </person-group>
            <article-title>Asthma specialist care preferences among parents of children receiving emergency department care for asthma.</article-title>
            <source>J Asthma</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-195</page-range>
            <pub-id pub-id-type="pmid">30663904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misra</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>The Current Evidence of Integrative Approaches to Pediatric Asthma.</article-title>
            <source>Curr Probl Pediatr Adolesc Health Care</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>190</fpage>
            <page-range>190-4</page-range>
            <pub-id pub-id-type="pmid">26832885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Axelsson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Naumburg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Prietsch</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Jun</month>
            <day>10</day>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>CD010126</fpage>
            <pub-id pub-id-type="pmid">31194879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clarridge</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eworuke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A Boxed Warning for Montelukast: The FDA Perspective.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>2638</fpage>
            <page-range>2638-2641</page-range>
            <pub-id pub-id-type="pmid">33744471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kakourou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asamoah</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Agache</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jutel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muraro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Akdis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bonini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavkaytar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Flood</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gajdanowicz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Izuhara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kalayci</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Mosges</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Palomares</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pfaar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Smolinska</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sokolowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Asaria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Netuveli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zaman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akhlaq</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis.</article-title>
            <source>Allergy</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>12</issue>
            <fpage>1825</fpage>
            <page-range>1825-1848</page-range>
            <pub-id pub-id-type="pmid">28543086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casale</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Chipps</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Ros&#x000e9;n</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Trzaskoma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Haselkorn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Omachi</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hanania</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.</article-title>
            <source>Allergy</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>490</fpage>
            <page-range>490-497</page-range>
            <pub-id pub-id-type="pmid">28859263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hardin</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Hackell</surname>
                <given-names>JM</given-names>
              </name>
              <collab>COMMITTEE ON PRACTICE AND AMBULATORY MEDICINE</collab>
            </person-group>
            <article-title>Age Limit of Pediatrics.</article-title>
            <source>Pediatrics</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>140</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">28827380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kew</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Dahri</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Jan</month>
            <day>21</day>
            <volume>2016</volume>
            <issue>1</issue>
            <fpage>CD011721</fpage>
            <pub-id pub-id-type="pmid">26798035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lovinsky-Desir</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The use of biologic therapies for the management of pediatric asthma.</article-title>
            <source>Pediatr Pulmonol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>803</fpage>
            <page-range>803-808</page-range>
            <pub-id pub-id-type="pmid">31880870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dweik</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Boggs</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Erzurum</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Irvin</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Leigh</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Lundberg</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Olin</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Plummer</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>DR</given-names>
              </name>
              <collab>American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications</collab>
            </person-group>
            <article-title>An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2011</year>
            <month>Sep</month>
            <day>01</day>
            <volume>184</volume>
            <issue>5</issue>
            <fpage>602</fpage>
            <page-range>602-15</page-range>
            <pub-id pub-id-type="pmid">21885636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Rogliani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matera</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>&#x003b2;2-agonist therapy in lung disease.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2013</year>
            <month>Apr</month>
            <day>01</day>
            <volume>187</volume>
            <issue>7</issue>
            <fpage>690</fpage>
            <page-range>690-6</page-range>
            <pub-id pub-id-type="pmid">23348973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Sperou</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Crotts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saude</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hartling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stang</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of adverse drug events associated with administration of common asthma medications in children.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>e0182738</fpage>
            <pub-id pub-id-type="pmid">28793336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dusser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ducharme</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Safety of tiotropium in patients with asthma.</article-title>
            <source>Ther Adv Respir Dis</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>13</volume>
            <fpage>1753466618824010</fpage>
            <pub-id pub-id-type="pmid">30795731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aljebab</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Choonara</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Conroy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of the toxicity of short-course oral corticosteroids in children.</article-title>
            <source>Arch Dis Child</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>101</volume>
            <issue>4</issue>
            <fpage>365</fpage>
            <page-range>365-70</page-range>
            <pub-id pub-id-type="pmid">26768830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Comstock</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Decory</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate.</article-title>
            <source>Int J Inflam</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>789623</fpage>
            <pub-id pub-id-type="pmid">22536546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buchman</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Side effects of corticosteroid therapy.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>289</fpage>
            <page-range>289-94</page-range>
            <pub-id pub-id-type="pmid">11588541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Granholm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Penketh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ryg&#x000e5;rd</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Aneman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perner</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The effect of systemic corticosteroids on the incidence of gastrointestinal bleeding in critically ill adults: a systematic review with meta-analysis.</article-title>
            <source>Intensive Care Med</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>45</volume>
            <issue>11</issue>
            <fpage>1540</fpage>
            <page-range>1540-1549</page-range>
            <pub-id pub-id-type="pmid">31501997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r44">
          <label>44</label>
          <element-citation publication-type="book">
            <chapter-title>Zafirlukast</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>6</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">31643251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r45">
          <label>45</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Glacy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Putnam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Godfrey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Falzon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mauger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Samson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <source>Treatments for Seasonal Allergic Rhinitis [Internet]</source>
            <publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name>
            <publisher-loc>Rockville (MD)</publisher-loc>
            <year>2013</year>
            <month>07</month>
            <pub-id pub-id-type="pmid">23946962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holgate</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Clinical evaluation of nedocromil sodium in asthma.</article-title>
            <source>Eur J Respir Dis Suppl</source>
            <year>1986</year>
            <volume>147</volume>
            <fpage>149</fpage>
            <page-range>149-59</page-range>
            <pub-id pub-id-type="pmid">3021489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tisdale</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Hammadah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Leclerc</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rajagopalan</surname>
                <given-names>B</given-names>
              </name>
              <collab>American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing</collab>
            </person-group>
            <article-title>Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2020</year>
            <month>Oct</month>
            <day>13</day>
            <volume>142</volume>
            <issue>15</issue>
            <fpage>e214</fpage>
            <page-range>e214-e233</page-range>
            <pub-id pub-id-type="pmid">32929996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balbino</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Herviou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Godon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Stackowicz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goff</surname>
                <given-names>OR</given-names>
              </name>
              <name>
                <surname>Iannascoli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sterlin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Br&#x000fb;l&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Millot</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Voronina</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Nadeau</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bruhns</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reber</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>The anti-IgE mAb omalizumab induces adverse reactions by engaging Fc&#x003b3; receptors.</article-title>
            <source>J Clin Invest</source>
            <year>2020</year>
            <month>Mar</month>
            <day>02</day>
            <volume>130</volume>
            <issue>3</issue>
            <fpage>1330</fpage>
            <page-range>1330-1335</page-range>
            <pub-id pub-id-type="pmid">31770111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fildan</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Rajnoveanu</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Cirjaliu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pohrib</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tudorache</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ilie</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Oancea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tofolean</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review).</article-title>
            <source>Exp Ther Med</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>1263</fpage>
            <pub-id pub-id-type="pmid">34603531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillette</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rockich-Winston</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuhn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Flesher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Inhaler Technique in Children With Asthma: A Systematic Review.</article-title>
            <source>Acad Pediatr</source>
            <year>2016</year>
            <season>Sep-Oct</season>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>605</fpage>
            <page-range>605-15</page-range>
            <pub-id pub-id-type="pmid">27130811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearce</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Adherence to medication in children and adolescents with asthma: methods for monitoring and intervention.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>12</issue>
            <fpage>1055</fpage>
            <page-range>1055-1063</page-range>
            <pub-id pub-id-type="pmid">30286679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Szefler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Halpin</surname>
                <given-names>DMG</given-names>
              </name>
            </person-group>
            <article-title>Impact of comorbid conditions on asthmatic adults and children.</article-title>
            <source>NPJ Prim Care Respir Med</source>
            <year>2020</year>
            <month>Aug</month>
            <day>20</day>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <pub-id pub-id-type="pmid">32820164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chupp</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>McEvoy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Silvestri</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Shifren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McClelland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dransfield</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trevor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kahlstrom</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Simoff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wahidi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lamb</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hogarth</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Tejedor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Majid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>LaCamera</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Enfield</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>McMullen</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Laviolette</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bronchial Thermoplasty in Patients With Severe Asthma at 5 Years: The Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma Study.</article-title>
            <source>Chest</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>161</volume>
            <issue>3</issue>
            <fpage>614</fpage>
            <page-range>614-628</page-range>
            <pub-id pub-id-type="pmid">34774528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thornton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hayes-Watson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Krouse</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Wildfire</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mvula</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lichtveld</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grimsley</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>KU</given-names>
              </name>
            </person-group>
            <article-title>Adapting and implementing an evidence-based asthma counseling intervention for resource-poor populations.</article-title>
            <source>J Asthma</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>8</issue>
            <fpage>825</fpage>
            <page-range>825-34</page-range>
            <pub-id pub-id-type="pmid">27049234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olufemi-Yusuf</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Makhinova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Guirguis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>"Being in Control of My Asthma Myself" Patient Experience of Asthma Management: A Qualitative Interpretive Description.</article-title>
            <source>Pharmacy (Basel)</source>
            <year>2018</year>
            <month>Nov</month>
            <day>15</day>
            <volume>6</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30445719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quirt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hildebrand</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Noya</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Asthma.</article-title>
            <source>Allergy Asthma Clin Immunol</source>
            <year>2018</year>
            <volume>14</volume>
            <issue>Suppl 2</issue>
            <fpage>50</fpage>
            <pub-id pub-id-type="pmid">30275843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reeves</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kenny</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Mulreany</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>McCown</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Jacknewitz-Woolard</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Echelmeyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Welsh</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Development and assessment of a low literacy, pictographic asthma action plan with clinical automation to enhance guideline-concordant care for children with asthma.</article-title>
            <source>J Asthma</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>655</fpage>
            <page-range>655-672</page-range>
            <pub-id pub-id-type="pmid">35658804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Battula</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arunashekar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nagarajan</surname>
                <given-names>VP</given-names>
              </name>
            </person-group>
            <article-title>A Prospective Study to Assess the Quality of Life in Children with Newly Diagnosed Asthma and Their Caregivers using the Pediatric Asthma Quality of Life Questionnaire.</article-title>
            <source>J Prim Care Community Health</source>
            <year>2020</year>
            <season>Jan-Dec</season>
            <volume>11</volume>
            <fpage>2150132720961272</fpage>
            <pub-id pub-id-type="pmid">33016181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazurek</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Syamlal</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Asthma, Asthma Attacks, and Emergency Department Visits for Asthma Among Working Adults - National Health Interview Survey, 2011-2016.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2018</year>
            <month>Apr</month>
            <day>06</day>
            <volume>67</volume>
            <issue>13</issue>
            <fpage>377</fpage>
            <page-range>377-386</page-range>
            <pub-id pub-id-type="pmid">29621204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zablotsky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>LI</given-names>
              </name>
            </person-group>
            <article-title>Concordance between survey reported childhood asthma and linked Medicaid administrative records.</article-title>
            <source>J Asthma</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-295</page-range>
            <pub-id pub-id-type="pmid">29771597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caridi</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Humann</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Stefaniak</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>LeBouf</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Virji</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Henneberger</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Occupation and task as risk factors for asthma-related outcomes among healthcare workers in New York City.</article-title>
            <source>Int J Hyg Environ Health</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>222</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-220</page-range>
            <pub-id pub-id-type="pmid">30327176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanannejad</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Alyasin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Esmaeilzadeh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nabavizadeh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Asthma and COVID-19 pandemic: focus on the eosinophil count and ACE2 expression.</article-title>
            <source>Eur Ann Allergy Clin Immunol</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>54</volume>
            <issue>6</issue>
            <fpage>284</fpage>
            <page-range>284-289</page-range>
            <pub-id pub-id-type="pmid">34503323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ioniuc</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miron</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lupu</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Starcea</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Azoicai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alexoae</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adam Raileanu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dragan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lupu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Challenges in the Pharmacotherapeutic Management of Pediatric Asthma.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2022</year>
            <month>Dec</month>
            <day>18</day>
            <volume>15</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">36559032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pate</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Zahran</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hummelman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Malilay</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Asthma Surveillance - United States, 2006-2018.</article-title>
            <source>MMWR Surveill Summ</source>
            <year>2021</year>
            <month>Sep</month>
            <day>17</day>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>1</fpage>
            <page-range>1-32</page-range>
            <pub-id pub-id-type="pmid">34529643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nwaru</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Ekstr&#x000f6;m</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hasvold</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Telg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Janson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Overuse of short-acting &#x003b2;<sub>2</sub>-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme.</article-title>
            <source>Eur Respir J</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>55</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">31949111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fonseca</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Monteiro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taborda-Barata</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Inhaled Drug Therapy-Associated Adverse Reactions in Obstructive Respiratory Diseases: A Review of a Decade of Reporting to the Portuguese Pharmacovigilance System.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2021</year>
            <month>Nov</month>
            <day>25</day>
            <volume>18</volume>
            <issue>23</issue>
            <pub-id pub-id-type="pmid">34886135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wahab</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Yaacob</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Noor</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Draman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>A Case Report of Steroid Withdrawal Syndrome.</article-title>
            <source>Korean J Fam Med</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>359</fpage>
            <page-range>359-362</page-range>
            <pub-id pub-id-type="pmid">32961047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fries</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>FW</given-names>
              </name>
            </person-group>
            <article-title>Acute on Chronic Theophylline Toxicity in an Elderly Patient.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Feb</month>
            <day>22</day>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>e13484</fpage>
            <pub-id pub-id-type="pmid">33777571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shiotsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yuba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hiraoka</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>e25218</fpage>
            <pub-id pub-id-type="pmid">35747049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tesse</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Borrelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mongelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mastrorilli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cardinale</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Treating Pediatric Asthma According Guidelines.</article-title>
            <source>Front Pediatr</source>
            <year>2018</year>
            <volume>6</volume>
            <fpage>234</fpage>
            <pub-id pub-id-type="pmid">30191146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wooler</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The role of the nurse in paediatric asthma management.</article-title>
            <source>Paediatr Respir Rev</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-81</page-range>
            <pub-id pub-id-type="pmid">16263484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Effects of physical therapy on lung function in children with asthma: a systematic review and meta-analysis.</article-title>
            <source>Pediatr Res</source>
            <year>2021</year>
            <month>May</month>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>1343</fpage>
            <page-range>1343-1351</page-range>
            <pub-id pub-id-type="pmid">32244247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Haynes</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Gates</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Heath</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Rehder</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>A Respiratory Therapist-Driven Asthma Pathway Reduced Hospital Length of Stay in the Pediatric Intensive Care Unit.</article-title>
            <source>Respir Care</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>64</volume>
            <issue>11</issue>
            <fpage>1325</fpage>
            <page-range>1325-1332</page-range>
            <pub-id pub-id-type="pmid">31088987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nikolaizik</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wuensch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bauck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sohrabi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weissflog</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hildebrandt</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Koehler</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pilot study on nocturnal monitoring of crackles in children with pneumonia.</article-title>
            <source>ERJ Open Res</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">34853781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ensom</surname>
                <given-names>MHH</given-names>
              </name>
              <name>
                <surname>Carr</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Survey of Therapeutic Drug Monitoring Practices in Pediatric Health Care Programs across Canada.</article-title>
            <source>Can J Hosp Pharm</source>
            <year>2019</year>
            <season>Mar-Apr</season>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-132</page-range>
            <pub-id pub-id-type="pmid">31036973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17921.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>ZS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of fatal asthma combined with a silent chest: A case report.</article-title>
            <source>J Int Med Res</source>
            <year>2020</year>
            <month>May</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>300060520925683</fpage>
            <pub-id pub-id-type="pmid">32466702</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
